SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2012 / Cilt: 36 - Sayı: 2

$^{99m}Tc$ labeled levofloxacin as an infection imaging agent: a novel method for labeling levofloxacin using cysteine·HCl as co-ligand and in vivo study

Nasir MAHMOOD
Zulfiqar Ali KHAN
Syed Ali Raza NAQVI
Malik Muhammad ISHFAQ
Saeed Ahmad NAGRA
Iftikhar Hussain BUKHARI
Abdullah Ijaz HUSSAIN
Sohail Anjum SHAHZAD
Asma HAQUE
Tanveer Hussain BOKHARI
Pages
267–277
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the case of the live S. aureus induced abscess model, the accumulation of $^{99m}Tc$-lefx at target was 3.96, which was higher than that of $^{99m}Tc$-ciprofloxacin ( $^{99m}Tc$-cifx), taken as the control.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Levofloxacin was labeled with $^{99m}Tc$ using cysteine·HCl as co-ligand and $SnCl_2.2H_2O$ as reducing agent.
📊
Key Findings & Data:After optimizing the conditions the labeling was performed at pH 5 using 1 mg of levofloxacin, 500 μg of cysteine· HCl, 50 μg of $SnCl_2.2H_2O$, and 15 min reaction time.
💡
Conclusion & Impact:In the case of the live S. aureus induced abscess model, the accumulation of $^{99m}Tc$-lefx at target was 3.96, which was higher than that of $^{99m}Tc$-ciprofloxacin ( $^{99m}Tc$-cifx), taken as the control.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Levofloxacin was labeled with $^{99m}Tc$ using cysteine·HCl as co-ligand and $SnCl_2.2H_2O$ as reducing agent. The influence of various parameters such as amount of cysteine·HCl, reducing agent, pH value, and reaction time on labeling process was studied. After optimizing the conditions the labeling was performed at pH 5 using 1 mg of levofloxacin, 500 μg of cysteine· HCl, 50 μg of $SnCl_2.2H_2O$, and 15 min reaction time. The radiochemical purity was determined with the help of instant thin layer chromatography (ITLC) and reverse phase high performance liquid chromatography (RP-HPLC) which was more than 95% and was stable for up to 6 h. Biodistribution of $^{99m}Tc$-levofloxacin ( $^{99m}Tc$-lefx) was studied in infection induced rat models using live Staphylococcus aureus and heat killed S. aureus (sterile inflammation model). In the case of the live S. aureus induced abscess model, the accumulation of $^{99m}Tc$-lefx at target was 3.96, which was higher than that of $^{99m}Tc$-ciprofloxacin ( $^{99m}Tc$-cifx), taken as the control.

🔖

Cite This Article

MAHMOOD, N., KHAN, Z. A., NAQVI, S. A. R., ISHFAQ, M. M., NAGRA, S. A., BUKHARI, I. H., HUSSAIN, A. I., SHAHZAD, S. A., HAQUE, A., BOKHARI, T. H. (2022). $^{99m}Tc$ labeled levofloxacin as an infection imaging agent: a novel method for labeling levofloxacin using cysteine·HCl as co-ligand and in vivo study. Turkish Journal of Chemistry, Cilt: 36 - Sayı: 2, 267–277. https://ajindex.com/articles/596840

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Naqvi, S. A. R.; Matzow, T.; Finucane, C.; Nagra, S. A.; Ishfaq, M. M.; Mather, S. J.; Sosabowski, J. Cancer Biotherapy & Radiopharmaceuticals 2010, 25, 89-95. 2. von Guggenberg, E.; Dietrich, H.; Skvortsova, I.; Gabriel, M.; Virgolini, I. J.; Decristoforo, C. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1209-1218
  2. Signore, A.; Annovazzi, A.; Barone, R.; Bonanno, E.; D’Alessandria, C.; Chianelli, M.; Mather, S. J.; Bottoni, U.; Panetta, C.; Innocenzi, D.; Scopinaro, F.; Calvieri, S. J. Nucl. Med. 2004, 45, 1647-1652
  3. Santin, M.; Podzamczer, D.; Ricart, I.; Mascar´o, J.; Ram´on, J. M.; Dominguez, A.; Ruf´ı, G.; Gudiol, A. F. Clin. Infect. Dis. 1995, 20, 652-656
  4. Froelich, J. W.; Swanson, D. Semin. Nucl. Med. 1984, 14, 128-140
  5. Buscombe, J. R.; Lui, D.; Ensing, G.; de Jong, R.; Ell, P. J. Eur. J. Nucl. Med. 1990, 16, 649-655
  6. Bhatnagar, A.; Singh, A. K.; Singh, T.; Shankar, L. R. Nuclear Medicine Communications 1995, 16, 1052-1062
  7. Flivik, G.; Sloth, M.; Rydholm, U.; Herrlin, K.; Lidgren, L. J. Nucl. Med. 1993, 34, 1646-1650
  8. Seral, C.; Barcia-Macay, M.; Mingeot-Leclercq, M. P.; Tulkens, P. M.; Bambeke, F. V. J. Antimicrob. Chemother. 2005, 55, 511-517
  9. Wagenlehner, F. M. E.; Krieger, J. N. Pelviperineology 2011, 30, 17-26
  10. Carratal`a, J.; Garcia-Vidal, C. Curr Opin Infect Dis 2010, 23, 152-157
  11. Falc´o, V.; Molina, I.; Juste, C.; Crespo, M.; Almirante, B.; Pigrau, C.; Ferrer, A.; Bravo, C.; Palomar, M.; Pahissa, A. Enferm. Infecc. Microbiol. Clin. 2006, 24, 360-364
  12. Griffin, A. T.; Peyrani, P.; Wiemken, T.; Arnold, F. Int J Tuberc Lung Dis 2010, 14, 495-499
  13. Pedro-Botet, M. L.; Garc´ıa-Cruz, A.; Tural, C.; Mateu, L.; Sopena, N.; Roure, S.; Rey-Joly, C.; Sabria, M. J. Chemother. 2006, 18, 559-561
  14. Drago, L.; De Vecchi, E.; Mombelli, B.; Nicola, L.; Valli, M.; Gismondo, M. R. J. Antimicrob. Chemother. 2001, 48, 37-45
  15. Solanki, K. K.; Bomanji, J.; Siraj, Q.; Small, M.; Britton, K. E. J. Nucl. Med. 1993, 34, 119P
  16. Shimpi, H. H.; Nair, N. Indian J. Nucl. Med. 2003, 18, 16
  17. EL-Ghany; Amin, E. A.; Kawy, A. M.; Amin, O. A. Journal of Labelled Compounds and Radiopharmaceuticals 2007, 50, 25-31
  18. Ibrahim, I. T.; Motaleb, M. A.; Attalah, K. M. Journal of Radioanalytical and Nuclear Chemistry 2010, 285, 431-436
  19. Siaens, R. H.; Rennen, H. J.; Boerman, O. C.; Dierckx, R.; Slegers, G. J. Nucl. Med. 2004, 45, 2088-2094
  20. Singh, A. K.; Verma, J.; Bhatnagar, A.; Ali, A. World J. Nucl. Med. 2003, 103-109